BioAtla
BCAB3.3250.75% ( -0.025 )
BioAtla (BCAB)
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer....
- Open
- 3.635
- High
- 3.700
- Low
- 3.270
- Prev. Close
- 3.350
- Volume
- 44.46K
- Turnover
- 152.44K
- Avg Price
- 3.429
- Bid/Ask Ratio
- --
- Amplitude
- 12.84%
- 52wk High
- 71.500
- Volume Ratio
- 1.30
- Turnover Ratio
- 3.21%
BioAtla Analyst Rating
View MoreForecast & Rating
Nov 28, 2025Price forecast
$500.0014937.59%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- TradingView · 18 hours ago
BCAB Q2'26 Earnings: EPS estimate is (8.50) USD
- Global Report · Jul 19 at 04:12 AM
The Divergence of Moats: Physical Infrastructure, Strategic Pivots, and Survival Mechanics
- Global Report · Jul 18 at 04:13 AM
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 Trajectory
- Global Report · Jul 17 at 04:12 AM
Market Signals Point to Growing Divergence in US Small-Cap Sector
- Global Report · Jul 15 at 04:14 AM
The tech fringes of 2026: AI lending, EV retreats, and the challengers still hanging on
- Global Report · Jul 14 at 06:47 AM
Mixed Signals from Micro Data: How U.S. Equities Are Navigating Sector Divergence
